CD274 and urothelial carcinoma: Given the varying association between PD-L1 expression and the efficacy of immune checkpoint inhibitors in urothelial carcinoma patients (37), it is increasingly important to explore the relationship between PD-L1 expression and the cost-effectiveness of these therapies.